{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T16:37:13Z","timestamp":1790786233735,"version":"4.1.0"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.ejpb.2019.08.004","type":"journal-article","created":{"date-parts":[[2019,8,6]],"date-time":"2019-08-06T16:51:34Z","timestamp":1565110294000},"page":"543-552","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":72,"special_numbering":"C","title":["Inhalable combination powder formulations of phage and ciprofloxacin for P. aeruginosa respiratory infections"],"prefix":"10.1016","volume":"142","author":[{"given":"Yu","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel Yoon Kyung","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Warwick J.","family":"Britton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Morales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Kutter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hak-Kim","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpb.2019.08.004_b0005","unstructured":"WHO, Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics, 2017. <https:\/\/www.who.int\/medicines\/publications\/WHO-PPL-Short_Summary_25Feb-ET_NM_WHO.pdf?ua=1> (accessed on 24th Februray 2019)."},{"key":"10.1016\/j.ejpb.2019.08.004_b0010","doi-asserted-by":"crossref","first-page":"e00019","DOI":"10.1128\/CMR.00019-18","article-title":"Epidemiology, biology, and impact of clonal Pseudomonas aeruginosa infections in cystic fibrosis","volume":"31","author":"Parkins","year":"2018","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.ejpb.2019.08.004_b0015","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.addr.2014.10.022","article-title":"Inhaled formulations and pulmonary drug delivery systems for respiratory infections","volume":"85","author":"Zhou","year":"2015","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2019.08.004_b0020","first-page":"02400","article-title":"Importance of site of infection and antibiotic selection in the treatment of carbapenem-resistant Pseudomonas aeruginosa sepsis","volume":"AAC","author":"Britt","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejpb.2019.08.004_b0025","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0378-5173(98)00055-6","article-title":"Regional lung deposition of nebulized liposome-encapsulated ciprofloxacin","volume":"167","author":"Finlay","year":"1998","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2019.08.004_b0030","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.jconrel.2017.12.021","article-title":"New aerosol formulation to control ciprofloxacin pulmonary concentration","volume":"271","author":"Lamy","year":"2018","journal-title":"J. Control. Release."},{"key":"10.1016\/j.ejpb.2019.08.004_b0035","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.ijpharm.2018.06.017","article-title":"A new therapeutic avenue for bronchiectasis: dry powder inhaler of ciprofloxacin nanoplex exhibits superior ex vivo mucus permeability and antibacterial efficacy to its native ciprofloxacin counterpart","volume":"547","author":"Tran","year":"2018","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2019.08.004_b0040","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.ejps.2010.03.020","article-title":"Co-spray-dried mannitol\u2013ciprofloxacin dry powder inhaler formulation for cystic fibrosis and chronic obstructive pulmonary disease","volume":"40","author":"Adi","year":"2010","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2019.08.004_b0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.pupt.2018.03.005","article-title":"Ciprofloxacin dry powder for inhalation (ciprofloxacin DPI): technical design and features of an efficient drug\u2013device combination","author":"McShane","year":"2018","journal-title":"Pulm. Pharmacol. Ther."},{"key":"10.1016\/j.ejpb.2019.08.004_b0050","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1080\/13543784.2017.1364728","article-title":"Inhaled or nebulised ciprofloxacin for the maintenance treatment of bronchiectasis","volume":"26","author":"Cartlidge","year":"2017","journal-title":"Expert. Opin. Investig. Drugs."},{"key":"10.1016\/j.ejpb.2019.08.004_b0055","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1021\/mp500586p","article-title":"Novel inhaled combination powder containing amorphous colistin and crystalline rifapentine with enhanced antimicrobial activities against planktonic cells and biofilm of Pseudomonas aeruginosa for respiratory infections","volume":"12","author":"Zhou","year":"2014","journal-title":"Mol Pharm."},{"key":"10.1016\/j.ejpb.2019.08.004_b0060","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1093\/jac\/dkp282","article-title":"Antibacterial activities of a fosfomycin\/tobramycin combination: a novel inhaled antibiotic for bronchiectasis","volume":"64","author":"MacLeod","year":"2009","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.ejpb.2019.08.004_b0065","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1208\/s12248-013-9537-8","article-title":"Synergistic antibiotic combination powders of colistin and rifampicin provide high aerosolization efficiency and moisture protection","volume":"16","author":"Zhou","year":"2014","journal-title":"AAPS J."},{"key":"10.1016\/j.ejpb.2019.08.004_b0070","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1016\/j.nano.2017.06.011","article-title":"Pulmonary delivery of synergistic combination of fluoroquinolone antibiotic complemented with proteolytic enzyme: A novel antimicrobial and antibiofilm strategy","volume":"13","author":"Gupta","year":"2017","journal-title":"Nanomedicine"},{"key":"10.1016\/j.ejpb.2019.08.004_b0075","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.ijpharm.2018.07.010","article-title":"Composite particle formulations of colistin and meropenem with improved in-vitro bacterial killing and aerosolization for inhalation","volume":"548","author":"Mangal","year":"2018","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2019.08.004_b0080","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1473-3099(15)00466-1","article-title":"Alternatives to antibiotics\u2014a pipeline portfolio review","volume":"16","author":"Czaplewski","year":"2016","journal-title":"Lancet. Infect. Dis."},{"key":"10.1016\/j.ejpb.2019.08.004_b0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2018.08.001","article-title":"Phage therapy for respiratory infections","author":"Chang","year":"2018","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2019.08.004_b0090","doi-asserted-by":"crossref","first-page":"69","DOI":"10.2174\/138920110790725401","article-title":"Phage therapy in clinical practice: treatment of human infections","volume":"11","author":"Kutter","year":"2010","journal-title":"Curr. Pharm. Biotechnol."},{"key":"10.1016\/j.ejpb.2019.08.004_b0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.resmic.2018.05.001","article-title":"Phage therapy against achromobacter xylosoxidans lung infection in a patient with cystic fibrosis: a case report","author":"Hoyle","year":"2018","journal-title":"Res. Microbiol."},{"key":"10.1016\/j.ejpb.2019.08.004_b0100","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.ijpharm.2018.09.024","article-title":"Synergy of nebulized phage PEV20 and ciprofloxacin combination against Pseudomonas aeruginosa","volume":"551","author":"Lin","year":"2018","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2019.08.004_b0105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejpb.2017.09.002","article-title":"Production of highly stable spray dried phage formulations for treatment of Pseudomonas aeruginosa lung infection","volume":"121","author":"Chang","year":"2017","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2019.08.004_b0110","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1615\/CritRevTherDrugCarrierSyst.v24.i4.10","article-title":"Spray-dried powders for pulmonary drug delivery","volume":"24","author":"Seville","year":"2007","journal-title":"Crit. Rev. Ther. Drug Carrier Syst."},{"key":"10.1016\/j.ejpb.2019.08.004_b0115","unstructured":"R. Wisniewski, Spray drying technology review, in: 45th International Conference on Environmental Systems, 2015."},{"key":"10.1016\/j.ejpb.2019.08.004_b0120","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.ijpharm.2018.04.034","article-title":"Influence of excipients on physical and aerosolization stability of spray dried high-dose powder formulations for inhalation","volume":"544","author":"Shetty","year":"2018","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2019.08.004_b0125","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ejpb.2016.02.010","article-title":"L-Leucine as an excipient against moisture on in vitro aerosolization performances of highly hygroscopic spray-dried powders","volume":"102","author":"Li","year":"2016","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2019.08.004_b0130","doi-asserted-by":"crossref","first-page":"5197","DOI":"10.1002\/jps.22715","article-title":"Spray-dried respirable powders containing bacteriophages for the treatment of pulmonary infections","volume":"100","author":"Matinkhoo","year":"2011","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2019.08.004_b0135","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1007\/s11095-016-1892-6","article-title":"Production of inhalation phage powders using spray freeze drying and spray drying techniques for treatment of respiratory infections","volume":"33","author":"Leung","year":"2016","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2019.08.004_b0140","first-page":"01714","article-title":"Anti-pseudomonal activity of phage PEV20 in a dry powder formulation\u2014a proof-of-principle study in a murine lung infection model","volume":"AAC","author":"Chang","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejpb.2019.08.004_b0145","doi-asserted-by":"crossref","first-page":"26717","DOI":"10.1038\/srep26717","article-title":"Phage selection restores antibiotic sensitivity in MDR Pseudomonas aeruginosa","volume":"6","author":"Chan","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejpb.2019.08.004_b0150","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/jps.23795","article-title":"Development and characterization of an in vitro release assay for liposomal ciprofloxacin for inhalation","volume":"103","author":"Cipolla","year":"2014","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2019.08.004_b0155","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.ejpb.2018.01.010","article-title":"Nebulization effects on structural stability of bacteriophage PEV 44","volume":"125","author":"Astudillo","year":"2018","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2019.08.004_b0160","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0168615","article-title":"Synergy and order effects of antibiotics and phages in killing Pseudomonas aeruginosa biofilms","volume":"12","author":"Chaudhry","year":"2017","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ejpb.2019.08.004_b0165","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1080\/17425247.2016.1224846","article-title":"Dry powder inhalation: past, present and future","volume":"14","author":"de Boer","year":"2017","journal-title":"Expert Opin. Drug Deliv"},{"key":"10.1016\/j.ejpb.2019.08.004_b0170","unstructured":"W.I.H.R. GOOD, The advantages of designing high-resistance swirl chambers for use in dry-powder inhalers."},{"key":"10.1016\/j.ejpb.2019.08.004_b0175","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1089\/jamp.2018.1497","article-title":"Idealhalers versus realhalers: is it possible to bypass deposition in the upper respiratory tract?","volume":"32","author":"Weers","year":"2019","journal-title":"J. Aeroso.l Med. Pulm. Drug. Deliv."},{"key":"10.1016\/j.ejpb.2019.08.004_b0180","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1007\/s11095-007-9262-z","article-title":"Influence of mouthpiece geometry on the aerosol delivery performance of a dry powder inhaler","volume":"24","author":"Coates","year":"2007","journal-title":"Pharm. Res"},{"key":"10.1016\/j.ejpb.2019.08.004_b0185","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s40261-013-0082-0","article-title":"Inhalation of a dry powder ciprofloxacin formulation in healthy subjects: a phase I study","volume":"33","author":"Stass","year":"2013","journal-title":"Clin. Drug. Invest."},{"key":"10.1016\/j.ejpb.2019.08.004_b0190","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.jcf.2009.04.005","article-title":"Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: a European consensus","volume":"8","author":"Heijerman","year":"2009","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.ejpb.2019.08.004_b0195","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s11095-017-2281-5","article-title":"Effects of moisture-induced crystallization on the aerosol performance of spray dried amorphous ciprofloxacin powder formulations","volume":"35","author":"Shetty","year":"2018","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2019.08.004_b0200","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.addr.2016.01.002","article-title":"Amorphous powders for inhalation drug delivery","volume":"100","author":"Chen","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2019.08.004_b0205","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.jconrel.2010.02.025","article-title":"A comparison between spray drying and spray freeze drying to produce an influenza subunit vaccine powder for inhalation","volume":"144","author":"Saluja","year":"2010","journal-title":"J. Control. Release."},{"key":"10.1016\/j.ejpb.2019.08.004_b0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2019.01.050","article-title":"Storage stability of inhalable phage powders containing lactose at ambient conditions","author":"Chang","year":"2019","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2019.08.004_b0215","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.ejpb.2018.02.033","article-title":"Effect of storage temperature on the stability of spray dried bacteriophage powders","volume":"127","author":"Leung","year":"2018","journal-title":"Eur. J. Pharm. Biopharm."}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641119303236?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641119303236?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T16:40:36Z","timestamp":1760546436000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641119303236"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":43,"alternative-id":["S0939641119303236"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2019.08.004","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inhalable combination powder formulations of phage and ciprofloxacin for P. aeruginosa respiratory infections","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2019.08.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}